期刊
LUNG CANCER MANAGEMENT
卷 2, 期 3, 页码 189-197出版社
FUTURE MEDICINE LTD
DOI: 10.2217/LMT.13.20
关键词
-
资金
- AbbVie (IL, USA)
- AbbVie
Aim: To identify contemporary first-and second-line treatment patterns for advanced non-small-cell lung cancer (aNSCLC) and associated costs. Methods: This study identified aNSCLC patients through an oncology registry linked to a large US commercial claims database. Patients with aNSCLC (stage IIIb or IV) and continuous enrollment in the health plan from diagnosis until death were included. First and second lines of therapy and their associated costs were determined. Results: The most common first-line regimens (n = 335) were platinum-taxane doublets alone (29%) or in combination with bevacizumab (14%) or pemetrexed (6%). Most second-line regimens (n = 74) contained pemetrexed, bevacizumab and/or erlotinib. Mean total healthcare costs ranged from US$19,182 to US$167,847 (first-line) and from US$35,737 to US$135,364 (second-line). Systemic therapy represented 20-55% of first-line and 22-68% of second-line total costs. Conclusion: Pemetrexed and targeted therapies are prevalent in both first-and second-line regimens. Total and systemic therapy-related costs exhibited considerable variability by regimen.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据